# A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

> **NCT02162888** · PHASE1 · COMPLETED · sponsor: **Eagle Pharmaceuticals, Inc.** · enrollment: 81 (actual)

## Conditions studied

- Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

## Interventions

- **DRUG:** Test Product (Bendamustine)

## Key facts

- **NCT ID:** NCT02162888
- **Lead sponsor:** Eagle Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162888, "A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02162888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*